>>Description of the research protocol "PRESEV2"

Validation d'un score prédictif de syndrome thoracique aigu (PRESERV 2)
Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Hématologie
Brugmann identifier : PRESEV2
EudraCT identifier : B077201629241


Involved department : Hemato-oncology
Principal investigator : Nifosi
Sponsor : APHP
Contact : Clinical Research Unit

>This protocol was approved by the Brugmann (monocentrique) ethics committee.